Maputo, 11 Aug (AIM) – The state-owned Mozambican pharmaceutical company (SMM) recorded, in 2025, a 98.5 percent drop in profits, which corresponds to 10.1 billion meticais (just over 158,000 US dollars at the current exchange rate).
In its financial statements, the company reports a positive net result in 2025, although well below the profit of 674.7 million meticais recorded in 2024. “2024 extraordinary gains resulted from an increase in value following a share capital increase at Mozambique Pharmaceutical Industry INFARMA carried out under the shareholders’ agreement, while the proportions of ownership held by the shareholders remained unchanged”, reads the document.
“The decline followed extraordinary results recorded in 2024, which were attributed to an increase in the value of the company’s financial stake in (INFARMA), in which it holds a 49 percent share”, the statement adds.
According to the company, sales declined in 2025, from 123.3 million meticais to 64.3 million meticais, a reduction of almost 48 percent. Consolidated accounts actually show a loss of 74.6 million meticais in 2025, after a profit of 639.9 million meticais in 2024.
“There was an increase in amounts receivable from customers, from 61.4 million meticais to 87.2 million meticais. The company faces a significant risk because it makes most of its sales on credit”, reads the document.
This drop in profits occurs at a moment when the National Health Service (SNS) is facing medicine shortage. According to the country’s National Medicine Regulatory Authority (ANARME), medicines and medical-surgical supplies budgeted at 20.8 million meticais were stolen from the National SNS, during the first half of 2026.
In its market oversight and anti-illegal-sales operations conducted during the first half of 2026, ANARME inspected 580 public and private establishments and confiscated almost 25,000 units of various types of medicines belonging to the SNS.
Am/
